130 results on '"Kotaro Hattori"'
Search Results
2. Deep learning-based corrosion inspection of long-span bridges with BIM integration
- Author
-
Kotaro Hattori, Keiichi Oki, Aya Sugita, Takeshi Sugiyama, and Pang-jo Chun
- Subjects
Corrosion ,Long-span bridge ,Deep learning ,BIM ,Optical flow ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Infrastructure operation and maintenance is essential for societal safety, particularly in Japan where the aging of infrastructures built during the period of high economic growth is advancing. However, there are issues such as a shortage of engineers and inefficiencies in work, requiring improvements in efficiency and automation for their resolution. Nevertheless, there are still many inefficiencies in the current procedures for bridge inspections. Usually, inspection engineers check for damage on bridges through close visual inspections at the site, then photograph the damaged parts, measure the size by touch, and create a report. A three-dimensional representation, considering the front and back of the structural elements, is needed for identifying damage, necessitating the creation of multi-directional three-dimensional drawings. However, this process is labor-intensive and prone to errors. Furthermore, due to the lack of uniformity in records, it is challenging to refer to past inspection histories. Especially for long bridges, without resolving such issues, the required labor and the number of mistakes could exceed acceptable limits, making proper management difficult. Therefore, in this study, we developed a method for automatically measuring the position and area of corroded parts by capturing images of the lower surface of the stiffening girder using a bridge inspection vehicle and utilizing image diagnosis technology. By integrating these results into a 3D model called BIM (Building Information Modeling), it becomes possible to manage the bridge more efficiently. We verified this method on actual long bridges and confirmed its effectiveness.
- Published
- 2024
- Full Text
- View/download PDF
3. Neuronal autoantibodies in the cerebrospinal fluid of 148 patients with schizophrenia and 151 healthy controls
- Author
-
Takako Enokida, Nanako Yoshida, Megumi Tatsumi, Shinsuke Hidese, Yu-ichi Goto, Mikio Hoshino, Hiroshi Kunugi, and Kotaro Hattori
- Subjects
Autoantibody ,Cerebrospinal fluid ,NMDA ,DFS70 ,Schizophrenia ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Schizophrenia is a syndrome with multiple etiologies, one of which is the potential for an autoimmune disease of the brain such as N-methyl-d-aspartate receptor (NMDAR) encephalitis, which can induce psychosis resembling schizophrenia. Here, we examined anti-neuronal autoantibodies related to psychosis using both cell- (CBA) and tissue-based assays (TBA) in the cerebrospinal fluid (CSF) of patients with chronic schizophrenia and control participants. First, we screened for the antibodies against leucine-rich glioma-inactivated 1 (LGI1), γ-aminobutyric acid B receptor (GABABR), dipeptidyl aminopeptidase-like protein 6 (DPPX), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR1/R2), and contactin-associated protein-like 2 (CASPR2) in 148 patients with schizophrenia. No antibodies were detected. Next, we performed CBA for NMDAR antibodies in 148 patients with schizophrenia and 151 age- and sex-matched controls. Although we detected relatively weak immunoreactivity for NMDAR in the CSFs of two patients with schizophrenia and three controls, no samples were positive when strict criteria were applied. For TBA in the rat hippocampus and cerebellum, we detected positive signals in the CSFs of 13 patients with schizophrenia and eight controls. Positive samples were analyzed for paraneoplastic syndrome and antinuclear antibodies using immunoblotting. The CSFs of nine patients and six controls were positive for dense fine speckle 70 (DFS70) antibodies. Additionally, antibodies against centromere protein (CENP)-A and CENP-B were detected in patients with schizophrenia. Our results suggest that autoantibodies against NMDAR, LG1, GABABR, DPPX, AMPAR1/R2, and CASPR2 are not associated with the pathogenesis of chronic schizophrenia. Moreover, we emphasize the importance of considering the effect of anti-DFS70 antibodies when analyzing autoantibodies in CSF samples. Conclusively, we obtained no evidence suggesting that the most frequent neuronal autoantibodies in the CSF play a role in the pathogenesis of schizophrenia, even in our sample.
- Published
- 2024
- Full Text
- View/download PDF
4. A homozygous structural variant of RPGRIP1 is frequently associated with achromatopsia in Japanese patients with IRD
- Author
-
Akiko Suga, Kei Mizobuchi, Taiga Inooka, Kazutoshi Yoshitake, Naoko Minematsu, Kazushige Tsunoda, Kazuki Kuniyoshi, Yosuke Kawai, Yosuke Omae, Katsushi Tokunaga, Takaaki Hayashi, Shinji Ueno, Takeshi Iwata, Hatsue Ishibashi-Ueda, Tsutomu Tomita, Michio Noguchi, Ayako Takahashi, Yu-ichi Goto, Sumiko Yoshida, Kotaro Hattori, Ryo Matsumura, Aritoshi Iida, Yutaka Maruoka, Hiroyuki Gatanaga, Masaya Sugiyama, Satoshi Suzuki, Kengo Miyo, Yoichi Matsubara, Akihiro Umezawa, Kenichiro Hata, Tadashi Kaname, Kouichi Ozaki, Haruhiko Tokuda, Hiroshi Watanabe, Shumpei Niida, Eisei Noiri, Koji Kitajima, Reiko Miyahara, and Hideyuki Shimanuki
- Subjects
Achromatopsia ,Genome sequencing ,RPGRIP1 ,Structural variant ,Genetics ,QH426-470 ,Medicine - Abstract
Purpose: Achromatopsia (ACHM) is an early-onset cone dysfunction caused by 5 genes with cone-specific functions (CNGA3, CNGB3, GNAT2, PDE6C, and PDE6H) and by ATF6, a transcription factor with ubiquitous expression. To improve the relatively low variant detection ratio in these genes in a cohort of exome-sequenced Japanese patients with inherited retinal diseases (IRD), we performed genome sequencing to detect structural variants and intronic variants in patients with ACHM. Methods: Genome sequencing of 10 ACHM pedigrees was performed after exome sequencing. Structural, non-coding, and coding variants were filtered based on segregation between the affected and unaffected in each pedigree. Variant frequency and predicted damage scores were considered in identifying pathogenic variants. Results: A homozygous deletion involving exon 18 of RPGRIP1 was detected in 5 of 10 ACHM probands, and variant inheritance from each parent was confirmed. This deletion was relatively frequent (minor allele frequency = 0.0023) in the Japanese population but was only homozygous in patients with ACHM among the 199 Japanese IRD probands analyzed by the same genome sequencing pipeline. Conclusion: The deletion involving exon 18 of RPGRIP1 is a prevalent cause of ACHM in Japanese patients and contributes to the wide spectrum of RPGRIP1-associated IRD phenotypes, from Leber congenital amaurosis to ACHM.
- Published
- 2024
- Full Text
- View/download PDF
5. Exploring the genetic diversity of the Japanese population: Insights from a large-scale whole genome sequencing analysis.
- Author
-
Yosuke Kawai, Yusuke Watanabe, Yosuke Omae, Reiko Miyahara, Seik-Soon Khor, Eisei Noiri, Koji Kitajima, Hideyuki Shimanuki, Hiroyuki Gatanaga, Kenichiro Hata, Kotaro Hattori, Aritoshi Iida, Hatsue Ishibashi-Ueda, Tadashi Kaname, Tatsuya Kanto, Ryo Matsumura, Kengo Miyo, Michio Noguchi, Kouichi Ozaki, Masaya Sugiyama, Ayako Takahashi, Haruhiko Tokuda, Tsutomu Tomita, Akihiro Umezawa, Hiroshi Watanabe, Sumiko Yoshida, Yu-Ichi Goto, Yutaka Maruoka, Yoichi Matsubara, Shumpei Niida, Masashi Mizokami, and Katsushi Tokunaga
- Subjects
Genetics ,QH426-470 - Abstract
The Japanese archipelago is a terminal location for human migration, and the contemporary Japanese people represent a unique population whose genomic diversity has been shaped by multiple migrations from Eurasia. We analyzed the genomic characteristics that define the genetic makeup of the modern Japanese population from a population genetics perspective from the genomic data of 9,287 samples obtained by high-coverage whole-genome sequencing (WGS) by the National Center Biobank Network. The dataset comprised populations from the Ryukyu Islands and other parts of the Japanese archipelago (Hondo). The Hondo population underwent two episodes of population decline during the Jomon period, corresponding to the Late Neolithic, and the Edo period, corresponding to the Early Modern era, while the Ryukyu population experienced a population decline during the shell midden period of the Late Neolithic in this region. Haplotype analysis suggested increased allele frequencies for genes related to alcohol and fatty acid metabolism, which were reported as loci that had experienced positive natural selection. Two genes related to alcohol metabolism were found to be 12,500 years out of phase with the time when they began to increase in the allele frequency; this finding indicates that the genomic diversity of Japanese people has been shaped by events closely related to agriculture and food production.
- Published
- 2023
- Full Text
- View/download PDF
6. Plasma neuropeptide levels in patients with schizophrenia, bipolar disorder, or major depressive disorder and healthy controls: A multiplex immunoassay study
- Author
-
Shinsuke Hidese, Fuyuko Yoshida, Ikki Ishida, Junko Matsuo, Kotaro Hattori, and Hiroshi Kunugi
- Subjects
cognitive function ,major psychiatric disorders ,neuropeptide ,symptom ,Therapeutics. Pharmacology ,RM1-950 ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Abstract Aim We aimed to compare neuropeptide levels between patients with major psychiatric disorders and healthy controls and examine their association with symptoms and cognitive function. Methods The participants were 149 patients with schizophrenia, 115 patients with bipolar disorder (BD), 186 unremitted patients with major depressive disorder (MDD), and 350 healthy controls. Psychiatric (schizophrenic, manic, and depressive) symptoms, sleep state, and cognitive (premorbid intelligence quotient, general cognitive, and memory) functions were evaluated. A multiplex immunoassay kit was used to measure cerebrospinal fluid (CSF) and plasma α‐melanocyte‐stimulating hormone (MSH), β‐endorphin, neurotensin, oxytocin, and substance P levels. Results The verification assay revealed that CSF α‐MSH, β‐endorphin, neurotensin, oxytocin, and substance P levels were too low to be reliably measured, while plasma α‐MSH, β‐endorphin, neurotensin, oxytocin, and substance P levels could be successfully measured. Plasma α‐MSH, β‐endorphin, neurotensin, oxytocin, and substance P levels were not significantly different between patients with schizophrenia, BD, or MDD and healthy controls. Plasma α‐MSH, β‐endorphin, neurotensin, oxytocin, and substance P levels were not significantly correlated with psychiatric symptom scores in patients with schizophrenia, BD, or MDD and cognitive function scores in patients or healthy controls. Conclusion Our data suggest that plasma neuropeptide levels do not elucidate the involvement of neuropeptides in the pathology of schizophrenia, BD, or MDD.
- Published
- 2023
- Full Text
- View/download PDF
7. Using brain cell-type-specific protein interactomes to interpret neurodevelopmental genetic signals in schizophrenia
- Author
-
Yu-Han H. Hsu, Greta Pintacuda, Ruize Liu, Eugeniu Nacu, April Kim, Kalliopi Tsafou, Natalie Petrossian, William Crotty, Jung Min Suh, Jackson Riseman, Jacqueline M. Martin, Julia C. Biagini, Daya Mena, Joshua K.T. Ching, Edyta Malolepsza, Taibo Li, Tarjinder Singh, Tian Ge, Shawn B. Egri, Benjamin Tanenbaum, Caroline R. Stanclift, Annie M. Apffel, Steven A. Carr, Monica Schenone, Jake Jaffe, Nadine Fornelos, Hailiang Huang, Kevin C. Eggan, Kasper Lage, Stephan Ripke, Benjamin M. Neale, Aiden Corvin, James T.R. Walters, Kai-How Farh, Peter A. Holmans, Phil Lee, Brendan Bulik-Sullivan, David A. Collier, Tune H. Pers, Ingrid Agartz, Esben Agerbo, Margot Albus, Madeline Alexander, Farooq Amin, Silviu A. Bacanu, Martin Begemann, Richard A. Belliveau, Jr., Judit Bene, Sarah E. Bergen, Elizabeth Bevilacqua, Tim B. Bigdeli, Donald W. Black, Richard Bruggeman, Nancy G. Buccola, Randy L. Buckner, William Byerley, Wiepke Cahn, Guiqing Cai, Dominique Campion, Rita M. Cantor, Vaughan J. Carr, Noa Carrera, Stanley V. Catts, Kimberley D. Chambert, Raymond C.K. Chan, Ronald Y.L. Chan, Eric Y.H. Chen, Wei Cheng, Eric FC. Cheung, Siow Ann Chong, C. Robert Cloninger, David Cohen, Nadine Cohen, Paul Cormican, Nick Craddock, James J. Crowley, David Curtis, Michael Davidson, Kenneth L. Davis, Franziska Degenhardt, Jurgen Del Favero, Ditte Demontis, Dimitris Dikeos, Timothy Dinan, Srdjan Djurovic, Gary Donohoe, Elodie Drapeau, Jubao Duan, Frank Dudbridge, Naser Durmishi, Peter Eichhammer, Johan Eriksson, Valentina Escott-Price, Laurent Essioux, Ayman H. Fanous, Martilias S. Farrell, Josef Frank, Lude Franke, Robert Freedman, Nelson B. Freimer, Marion Friedl, Joseph I. Friedman, Menachem Fromer, Giulio Genovese, Lyudmila Georgieva, Ina Giegling, Paola Giusti-Rodríguez, Stephanie Godard, Jacqueline I. Goldstein, Vera Golimbet, Srihari Gopal, Jacob Gratten, Lieuwe de Haan, Christian Hammer, Marian L. Hamshere, Mark Hansen, Thomas Hansen, Vahram Haroutunian, Annette M. Hartmann, Frans A. Henskens, Stefan Herms, Joel N. Hirschhorn, Per Hoffmann, Andrea Hofman, Mads V. Hollegaard, David M. Hougaard, Masashi Ikeda, Inge Joa, Antonio Julià, René S. Kahn, Luba Kalaydjieva, Sena Karachanak-Yankova, Juha Karjalainen, David Kavanagh, Matthew C. Keller, James L. Kennedy, Andrey Khrunin, Yunjung Kim, Janis Klovins, James A. Knowles, Bettina Konte, Vaidutis Kucinskas, Zita Ausrele Kucinskiene, Hana Kuzelova-Ptackova, Anna K. Kähler, Claudine Laurent, Jimmy Lee, S. Hong Lee, Sophie E. Legge, Bernard Lerer, Miaoxin Li, Tao Li, Kung-Yee Liang, Jeffrey Lieberman, Svetlana Limborska, Carmel M. Loughland, Jan Lubinski, Jouko Lönnqvist, Milan Macek, Patrik K.E. Magnusson, Brion S. Maher, Wolfgang Maier, Jacques Mallet, Sara Marsal, Manuel Mattheisen, Morten Mattingsdal, Robert W. McCarley, Colm McDonald, Andrew M. McIntosh, Sandra Meier, Carin J. Meijer, Bela Melegh, Ingrid Melle, Raquelle I. Mesholam-Gately, Andres Metspalu, Patricia T. Michie, Lili Milani, Vihra Milanova, Younes Mokrab, Derek W. Morris, Ole Mors, Kieran C. Murphy, Robin M. Murray, Inez Myin-Germeys, Bertram Müller-Myhsok, Mari Nelis, Igor Nenadic, Deborah A. Nertney, Gerald Nestadt, Kristin K. Nicodemus, Liene Nikitina-Zake, Laura Nisenbaum, Annelie Nordin, Eadbhard O'Callaghan, Colm O'Dushlaine, F. Anthony O'Neill, Sang-Yun Oh, Ann Olincy, Line Olsen, Jim Van Os, Christos Pantelis, George N. Papadimitriou, Sergi Papiol, Elena Parkhomenko, Michele T. Pato, Tiina Paunio, Milica Pejovic-Milovancevic, Diana O. Perkins, Olli Pietiläinen, Jonathan Pimm, Andrew J. Pocklington, John Powell, Alkes Price, Ann E. Pulver, Shaun M. Purcell, Digby Quested, Henrik B. Rasmussen, Abraham Reichenberg, Mark A. Reimers, Alexander L. Richards, Joshua L. Roffman, Panos Roussos, Douglas M. Ruderfer, Veikko Salomaa, Alan R. Sanders, Ulrich Schall, Christian R. Schubert, Thomas G. Schulze, Sibylle G. Schwab, Edward M. Scolnick, Rodney J. Scott, Larry J. Seidman, Jianxin Shi, Engilbert Sigurdsson, Teimuraz Silagadze, Jeremy M. Silverman, Kang Sim, Petr Slominsky, Jordan W. Smoller, Hon-Cheong So, Chris C.A. Spencer, Eli A. Stahl, Hreinn Stefansson, Stacy Steinberg, Elisabeth Stogmann, Richard E. Straub, Eric Strengman, Jana Strohmaier, T Scott Stroup, Mythily Subramaniam, Jaana Suvisaari, Dragan M. Svrakic, Jin P. Szatkiewicz, Erik Söderman, Srinivas Thirumalai, Draga Toncheva, Sarah Tosato, Juha Veijola, John Waddington, Dermot Walsh, Dai Wang, Qiang Wang, Bradley T. Webb, Mark Weiser, Dieter B. Wildenauer, Nigel M. Williams, Stephanie Williams, Stephanie H. Witt, Aaron R. Wolen, Emily H.M. Wong, Brandon K. Wormley, Hualin Simon Xi, Clement C. Zai, Xuebin Zheng, Fritz Zimprich, Naomi R. Wray, Kari Stefansson, Peter M. Visscher, Rolf Adolfsson, Ole A. Andreassen, Douglas H.R. Blackwood, Elvira Bramon, Joseph D. Buxbaum, Anders D. Børglum, Sven Cichon, Ariel Darvasi, Enrico Domenici, Hannelore Ehrenreich, Tõnu Esko, Pablo V. Gejman, Michael Gill, Hugh Gurling, Christina M. Hultman, Nakao Iwata, Assen V. Jablensky, Erik G. Jönsson, Kenneth S. Kendler, George Kirov, Jo Knight, Todd Lencz, Douglas F. Levinson, Qingqin S. Li, Jianjun Liu, Anil K. Malhotra, Steven A. McCarroll, Andrew McQuillin, Jennifer L. Moran, Preben B. Mortensen, Bryan J. Mowry, Markus M. Nöthen, Roel A. Ophoff, Michael J. Owen, Aarno Palotie, Carlos N. Pato, Tracey L. Petryshen, Danielle Posthuma, Marcella Rietschel, Brien P. Riley, Dan Rujescu, Pak C. Sham, Pamela Sklar, David St Clair, Daniel R. Weinberger, Jens R. Wendland, Thomas Werge, Mark J. Daly, Patrick F. Sullivan, Michael C. O'Donovan, Shengying Qin, Akira Sawa, Rene Kahn, Kyung Sue Hong, Wenzhao Shi, Ming Tsuang, Masanari Itokawa, Gang Feng, Stephen J. Glatt, Xiancang Ma, Jinsong Tang, Yunfeng Ruan, Feng Zhu, Yasue Horiuchi, Byung Dae Lee, Eun-Jeong Joo, Woojae Myung, Kyooseob Ha, Hong-Hee Won, Ji Hyung Baek, Young Chul Chung, Sung-Wan Kim, Agung Kusumawardhani, Wei J. Chen, Hai-Gwo Hwu, Akitoyo Hishimoto, Ikuo Otsuka, Ichiro Sora, Tomoko Toyota, Takeo Yoshikawa, Hiroshi Kunugi, Kotaro Hattori, Sayuri Ishiwata, Shusuke Numata, Tetsuro Ohmori, Makoto Arai, Yuji Ozeki, Kumiko Fujii, Se Joo Kim, Heon-Jeong Lee, Yong Min Ahn, Se Hyun Kim, Kazufumi Akiyama, Kazutaka Shimoda, and Makoto Kinoshita
- Subjects
Molecular interaction ,Developmental neuroscience ,Cellular neuroscience ,Proteomics ,Science - Abstract
Summary: Genetics have nominated many schizophrenia risk genes and identified convergent signals between schizophrenia and neurodevelopmental disorders. However, functional interpretation of the nominated genes in the relevant brain cell types is often lacking. We executed interaction proteomics for six schizophrenia risk genes that have also been implicated in neurodevelopment in human induced cortical neurons. The resulting protein network is enriched for common variant risk of schizophrenia in Europeans and East Asians, is down-regulated in layer 5/6 cortical neurons of individuals affected by schizophrenia, and can complement fine-mapping and eQTL data to prioritize additional genes in GWAS loci. A sub-network centered on HCN1 is enriched for common variant risk and contains proteins (HCN4 and AKAP11) enriched for rare protein-truncating mutations in individuals with schizophrenia and bipolar disorder. Our findings showcase brain cell-type-specific interactomes as an organizing framework to facilitate interpretation of genetic and transcriptomic data in schizophrenia and its related disorders.
- Published
- 2023
- Full Text
- View/download PDF
8. Association of body mass index and its classifications with gray matter volume in individuals with a wide range of body mass index group: A whole-brain magnetic resonance imaging study
- Author
-
Shinsuke Hidese, Miho Ota, Junko Matsuo, Ikki Ishida, Yuuki Yokota, Kotaro Hattori, Yukihito Yomogida, and Hiroshi Kunugi
- Subjects
BMI ,body mass index ,gray matter volume (GMV) ,magnetic resonance imaging ,obese ,overweight ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
AimTo examine the association of body mass index (BMI) [kg/m2] and its classifications (underweight [BMI < 18.5], normal [18.5 ≤ BMI < 25], overweight [25 ≤ BMI < 30], and obese [BMI ≥ 30]) with brain structure in individuals with a wide range of BMI group.Materials and methodsThe participants included 382 right-handed individuals (mean age: 46.9 ± 14.3 years, 142 men and 240 women). The intelligence quotient was assessed using the Japanese Adult Reading Test. Voxel-based morphometry (VBM) and diffusion tensor imaging (DTI) were performed to analyze the association of BMI and its classifications with gray and white matter structures, respectively.ResultsAccording to VBM, BMI was significantly and negatively correlated with the bilateral cerebellum exterior volumes. In group comparisons, the right cerebellum exterior volume was significantly lower in the overweight or obese group than in the underweight or normal group, while the bilateral cuneus and calcarine cortex, left cuneus, and left precuneus volume was significantly lower in the underweight group than in the non-underweight group. Sex-related stratification analyses for VBM revealed that BMI was significantly and negatively correlated with the bilateral cerebellum exterior volumes only in women. In group comparisons, the left cerebellum exterior volume was significantly lower in obese women than in non-obese women. The left thalamus proper and the right cerebellum exterior volumes were significantly lower in overweight or obese group than in underweight or normal group in men and women, respectively. The bilateral cuneus and calcarine cortex, left cuneus and carcarine cortex, and bilateral cuneus volume was significantly lower in underweight men than in non-underweight men. In contrast, there were no notable findings on DTI.ConclusionOur results suggest association of continuous BMI, being overweight or obese, and being underweight with decreased gray matter volume in individuals with a wide range of BMI group. Furthermore, sex-related differences are seen in the association of BMI and its classifications with regional gray matter volume reductions. Abnormally high or low BMIs may have a negative influence on regional gray matter volumes.
- Published
- 2022
- Full Text
- View/download PDF
9. Relationship between Interpersonal Sensitivity Measure score and clinical symptoms in patients with major psychiatric disorders and healthy individuals
- Author
-
Shinsuke Hidese, Junko Matsuo, Ikki Ishida, Yuuki Yokota, Miho Ota, Kotaro Hattori, and Hiroshi Kunugi
- Subjects
healthy individuals ,Interpersonal Sensitivity Measure ,major psychiatric disorders ,symptom ,Psychiatry ,RC435-571 - Abstract
Abstract Aim We compared the Interpersonal Sensitivity Measure (IPSM) scores between diagnostic groups and examined the relationship between IPSM scores and clinical variables. Methods This study included 166 patients with schizophrenia, 47 patients with bipolar disorder (BD) Ⅰ, 110 patients with BD Ⅱ, 380 patients with major depressive disorder (MDD), and 558 healthy individuals. Symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS), Young Mania Rating Scale, 21‐item Hamilton Depression Rating Scale (HAMD‐21), and Pittsburgh Sleep Quality Index (PSQI). Results The IPSM interpersonal awareness, separation anxiety, timidity, fragile inner self, and total scores were significantly higher in all the patient groups compared with healthy individuals (corrected p
- Published
- 2022
- Full Text
- View/download PDF
10. Possible associations between plasma fibroblast growth factor 21 levels and cognition in bipolar disorder
- Author
-
Favour Omileke, Sayuri Ishiwata, Junko Matsuo, Fuyuko Yoshida, Shinsuke Hidese, Kotaro Hattori, and Hiroshi Kunugi
- Subjects
bipolar disorder ,cognitive impairment ,FGF21 ,Therapeutics. Pharmacology ,RM1-950 ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Abstract Bipolar disorder (BD) is a mental disorder characterized by extreme changes in mood polarity. It is also characterized by cognitive and metabolic dysfunctions. Fibroblast growth factor 21 (FGF21) is an endocrine protein that has a multifaceted function such as glucose and lipid regulation in the periphery, and neuroprotection and induction of synaptic plasticity in the central nervous system. Previous studies reported inconsistent results concerning peripheral FGF21 levels in patients with BD. In this study, we compared plasma FGF21 levels between 26 patients with BD and 51 healthy controls using a human FGF21 ELISA Kit. There was no significant difference in plasma FGF21 levels between the patients and controls. We found significant positive correlations between plasma FGF21 levels and some cognitive parameters (word association and motor speed). If our results are replicated that higher peripheral FGF21 may be associated with better cognitive performance in patients with BD.
- Published
- 2020
- Full Text
- View/download PDF
11. Increased apolipoprotein E and decreased TNF‐α in the cerebrospinal fluid of nondemented APOE‐ε4 carriers
- Author
-
Daimei Sasayama, Kotaro Hattori, Yuuki Yokota, Ryo Matsumura, Toshiya Teraishi, Sumiko Yoshida, and Hiroshi Kunugi
- Subjects
alzheimer disease ,apolipoproteins E ,biomarkers ,cerebrospinal fluid proteins ,tumor necrosis factor‐alpha ,Therapeutics. Pharmacology ,RM1-950 ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Abstract Aim The ε4 allele of apolipoprotein E gene (APOE) is a well‐known risk factor of late‐onset Alzheimer's disease. However, little is known why this variant confers a risk for Alzheimer's disease. The aim of this study was to examine the influence of the APOE genotype on cerebrospinal fluid (CSF) protein levels. Methods The present study performed a secondary analysis on our previously generated database to compare the CSF levels of 1128 proteins between APOE‐ε4 carriers (28 subjects) and noncarriers (104 subjects). All subjects were physically healthy Japanese individuals without dementia. Results CSF levels of apoE2, apoE3, and apoE4 were significantly higher (all nominal P
- Published
- 2020
- Full Text
- View/download PDF
12. Neuroanatomical basis of harm avoidance personality traits in major depressive disorder
- Author
-
Yukihito Yomogida, Miho Ota, Junko Matsuo, Ikki Ishida, Shinsuke Hidese, Toshiya Teraishi, Noriko Sato, Hiroshi Matsuda, Kotaro Hattori, and Hiroshi Kunugi
- Subjects
Depression ,VBM ,TCI ,Harm avoidance ,Personality ,vMPFC ,Mental healing ,RZ400-408 - Abstract
Background: : Behavioral inhibition, referred to as the harm avoidance (HA) trait, has been deemed a vulnerability factor for major depressive disorder (MDD). Previous studies tried to find brain structural biomarkers of HA by assessing the relationship between interindividual variability in this trait and brain morphology. However, only healthy participants were recruited for these studies, and the results were heterogeneous. Methods: : To clarify the neural link between HA and MDD, we obtained magnetic resonance imaging data from the brains of 331 healthy people and 89 patients with MDD. Voxel-based morphometry (VBM) analyses were conducted to identify brain regions in which the gray matter volume was correlated with the HA score across participants and was simultaneously reduced in MDD patients. Results: : We found that the ventral part of the medial preferential cortex (vMPFC) fulfilled these criteria. Limitations: : The majority of the patients in this study were medicated with antidepressants. Conclusions: : The present finding suggests that reduced gray matter volume in this region is the neuropathology of high HA observed among MDD patients and might be the underlying reason why people with high HA are vulnerable to developing depression. Our findings may contribute to a deeper understanding of the neuropathology of MDD and provide insight into the brain regions of interest for predicting the development of the illness in the future.
- Published
- 2021
- Full Text
- View/download PDF
13. Association between lower estimated premorbid intelligence quotient and smoking behavior in patients with schizophrenia
- Author
-
Shinsuke Hidese, Junko Matsuo, Ikki Ishida, Moeko Hiraishi, Toshiya Teraishi, Miho Ota, Kotaro Hattori, and Hiroshi Kunugi
- Subjects
Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Aim: We aimed to investigate the involvement of premorbid intelligence quotient in higher prevalence of smoking in patients with schizophrenia. Methods: Participants included 190 patients with schizophrenia (mean ± standard deviation age: 37.7 ± 10.8 years; 88 males and 102 females) and 312 healthy individuals (mean ± standard deviation age: 38.1 ± 13.8; 166 males and 146 females), matched for age, sex, and ethnicity (Japanese). Premorbid intelligence quotient was estimated using the Japanese Adult Reading Test and distress symptoms were assessed using the Hopkins Symptom Check List. Current smoking information was collected according to self-declarations. Results: As expected, the smoking rate was higher, while mean education level and Japanese Adult Reading Test scores were significantly lower, in patients with schizophrenia than in healthy individuals (p
- Published
- 2019
- Full Text
- View/download PDF
14. Nervonic acid level in cerebrospinal fluid is a candidate biomarker for depressive and manic symptoms: A pilot study
- Author
-
Yuki Kageyama, Yasuhiko Deguchi, Kotaro Hattori, Sumiko Yoshida, Yu‐ichi Goto, Koki Inoue, and Tadafumi Kato
- Subjects
biomarker ,bipolar disorder ,cerebrospinal fluid ,major depressive disorder ,nervonic acid ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Abstract Objective Our previous metabolomics study showed that the plasma nervonic acid levels were higher in patients with major depressive disorder (MDD) than those in healthy controls and patients with bipolar disorder (BD). To examine whether the nervonic acid levels differ in the central nervous system, we investigated the levels in the cerebrospinal fluid (CSF) of patients with MDD, BD, and healthy controls. Methods Nervonic acid levels in CSF were measured by gas chromatography time‐of‐flight mass spectrometry. The participants included 30 patients with MDD, 30 patients with BD, and 30 healthy controls. Results In contrast to our previous study, no significant differences were found in the nervonic acid level in the CSF among the patients with MDD, BD, and the healthy controls. Though no significant state‐dependent changes were found among the three groups, we did observe a significant negative correlation between the nervonic acid levels and depressive symptoms in the depressive state of patients with MDD and BD (r = −0.38, p = .046). Further, a significant positive correlation was found between the nervonic acid levels and manic symptoms in the manic state of patients with BD (r = 0.79, p = .031). Conclusion The nervonic acid levels in the CSF did not differ among the patients with MDD, BD, and the healthy controls; however, a significant negative correlation with depressive symptoms and a positive correlation with manic symptoms was observed. Thus, the nervonic acid levels in the CSF may be a candidate biomarker for mood symptoms.
- Published
- 2021
- Full Text
- View/download PDF
15. Cerebrospinal Fluid Inflammatory Cytokine Levels in Patients With Major Psychiatric Disorders: A Multiplex Immunoassay Study
- Author
-
Shinsuke Hidese, Kotaro Hattori, Daimei Sasayama, Takuya Tsumagari, Tomoko Miyakawa, Ryo Matsumura, Yuuki Yokota, Ikki Ishida, Junko Matsuo, Sumiko Yoshida, Miho Ota, and Hiroshi Kunugi
- Subjects
bipolar disorder ,cerebrospinal fluid ,cytokine ,major depressive disorder ,multiplex ,schizophrenia ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Aim: Accumulating evidence suggests that neural inflammation plays an important role in psychiatric disorders. We aimed to identify inflammatory cytokines involved in the pathophysiology of such disorders by quantifying them in cerebrospinal fluid (CSF) samples from a large sample of patients with major psychiatric disorders and healthy controls.Methods: The subjects included 94 patients with schizophrenia, 68 with bipolar disorder, 104 with major depressive disorder, and 118 healthy controls, matched for age, sex, and ethnicity (Japanese). Lumbar puncture was performed to collect these CSF samples. A multiplex immunoassay was then performed to measure CSF cytokine levels using magnetic on-bead antibody conjugation for 19 inflammatory cytokines.Results: CSF interferon-β level was significantly higher in total psychiatric patients than in healthy controls (corrected p = 0.000029). In diagnostic group comparisons, CSF interferon-β level was significantly higher in patients with schizophrenia, or bipolar disorder (corrected p = 0.000047 or 0.0034) than in healthy controls.Conclusion: We present novel evidence that CSF IFN-β level showed prominent statistical differences between psychiatric groups and healthy controls. This suggests IFN-β as the most important player among the 19 cytokines tested here in the inflammation-related pathophysiology of major psychiatric disorders.
- Published
- 2021
- Full Text
- View/download PDF
16. Dry sliding wear resistance characterization of titanium matrix composites reinforced with titanium carbonitrides
- Author
-
Hiroshi IZUI, Kotaro HATTORI, and Yoshiki KOMIYA
- Subjects
pure titanium ,ti-6al-4v alloy ,titanium carbonitrides (tic1-xnx) ,tic0.3n0.7 ,tic0.7n0.3 ,titanium matrix composites ,dry sliding wear resistance ,Mechanical engineering and machinery ,TJ1-1570 - Abstract
Pure Ti and Ti-6Al-4V alloy show high specific strength, excellent fatigue strength and good corrosion resistance; however, their poor wear resistance limits potentially wider application. To improve the wear resistance of pure Ti and Ti-6Al-4V alloy, they were reinforced with two types of titanium carbonitrides (TiC1-xNx), TiC0.3N0.7 (N rich) and TiC0.7N0.3 (C rich). The composites with 2.5, 5.0, 7.5 and 10.0 vol.% reinforcement were fabricated by spark plasma sintering (SPS). Dry wear tests of the composites were performed against a 10 mm-diameter high-carbon-chromium steel ball under 23 N normal load, at a sliding speed of 100 mm/s and a sliding distance of 500 m using a ball-on-disk configuration. The pure Ti and Ti-6Al-4V alloy matrix composites with TiC0.3N0.7 showed good wear resistance compared to the composites with TiC0.7N0.3. For the TiC0.3N0.7 reinforcement, the pure Ti matrix composite showed better wear resistance than the Ti-6Al-4V alloy matrix composite. The specific wear rate of the pure Ti matrix composite containing 10 vol.% TiC0.3N0.7 was almost zero. The amount of nitrogen diffused into the titanium matrix was higher than that of carbon diffused into the matrix. The Vickers hardnesses of the composites with TiC0.3N0.7 were higher than those of the composites with TiC0.7N0.3, due to the solid solution strengthening of the nitrogen in the Ti matrix. Therefore, the dry sliding wear characteristics of the titanium matrix composites depended on the amount of nitrogen diffused into the Ti matrix.
- Published
- 2020
- Full Text
- View/download PDF
17. Corrigendum: Correlation Between the Wechsler Adult Intelligence Scale- 3rd Edition Metrics and Brain Structure in Healthy Individuals: A Whole-Brain Magnetic Resonance Imaging Study
- Author
-
Shinsuke Hidese, Miho Ota, Junko Matsuo, Ikki Ishida, Moeko Hiraishi, Yuuki Yokota, Kotaro Hattori, Yukihito Yomogida, and Hiroshi Kunugi
- Subjects
gray matter ,healthy individuals ,Japanese Adult Reading Test ,Wechsler Adult Intelligence Scale ,white matter ,whole-brain magnetic resonance imaging ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Published
- 2020
- Full Text
- View/download PDF
18. Correlation Between the Wechsler Adult Intelligence Scale- 3rd Edition Metrics and Brain Structure in Healthy Individuals: A Whole-Brain Magnetic Resonance Imaging Study
- Author
-
Shinsuke Hidese, Miho Ota, Junko Matsuo, Ikki Ishida, Moeko Hiraishi, Yuuki Yokota, Kotaro Hattori, Yukihito Yomogida, and Hiroshi Kunugi
- Subjects
gray matter ,healthy individuals ,Japanese Adult Reading Test ,Wechsler Adult Intelligence Scale ,white matter ,whole-brain magnetic resonance imaging ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
BackgroundThe Wechsler Adult Intelligence Scale, 3rd edition (WAIS-III) is widely used to evaluate the intelligence quotient (IQ). We aimed to investigate the correlation between the WAIS-III metrics and whole-brain structures using magnetic resonance imaging.MethodsThe participants were 266 healthy, right-handed individuals (age: 45.6 ± 12.9 years, 98 males and 168 females). IQs were evaluated using the WAIS-III and Japanese Adult Reading Test (JART). Voxel-based morphometry and diffusion tensor imaging were performed to analyze the correlation of the WAIS-III metrics and JART score with the gray matter volume and white matter integrity, respectively.ResultsThe verbal IQ significantly and positively correlated with the left gyrus rectus and anterior cingulate gyrus, left posterior insula and planum polare, and left superior and middle frontal gyri volumes (p < 0.05, corrected). The verbal comprehension group index significantly and positively correlated with the left superior and middle frontal gyri, left gyrus rectus and anterior cingulate gyrus, and left middle frontal gyrus volumes, while the processing speed group index significantly and positively correlated with the bilateral various regional white matter fractional anisotropy values (p < 0.05, corrected). In contrast, the JART score showed no correlation with any brain structure.ConclusionThese results suggested the neurostructural bases of the WAIS-III IQs and group indices in the brain of healthy individuals.
- Published
- 2020
- Full Text
- View/download PDF
19. Comparative analysis of cerebrospinal fluid metabolites in Alzheimer’s disease and idiopathic normal pressure hydrocephalus in a Japanese cohort
- Author
-
Yuki Nagata, Akiyoshi Hirayama, Satsuki Ikeda, Aoi Shirahata, Futaba Shoji, Midori Maruyama, Mitsunori Kayano, Masahiko Bundo, Kotaro Hattori, Sumiko Yoshida, Yu-ichi Goto, Katsuya Urakami, Tomoyoshi Soga, Kouichi Ozaki, and Shumpei Niida
- Subjects
Alzheimer’s disease ,Idiopathic normal pressure hydrocephalus ,Diagnostic marker ,Cerebrospinal fluid ,Serine ,Glycerate ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Abstract Background Alzheimer’s disease (AD) is a most common dementia in elderly people. Since AD symptoms resemble those of other neurodegenerative diseases, including idiopathic normal pressure hydrocephalus (iNPH), it is difficult to distinguish AD from iNPH for a precise and early diagnosis. iNPH is caused by the accumulation of cerebrospinal fluid (CSF) and involves gait disturbance, urinary incontinence, and dementia. iNPH is treatable with shunt operation which removes accumulated CSF from the brain ventricles. Methods We performed metabolomic analysis in the CSF of patients with AD and iNPH with capillary electrophoresis-mass spectrometry. We assessed metabolites to discriminate between AD and iNPH with Welch’s t-test, receiver operating characteristic (ROC) curve analysis, and multiple logistic regression analysis. Results We found significant increased levels of glycerate and N-acetylneuraminate and significant decreased levels of serine and 2-hydroxybutyrate in the CSF of patients with AD compared to the CSF of patients with iNPH. The ROC curve analysis with these four metabolites showed that the area under the ROC curve was 0.90, indicating good discrimination between AD and iNPH. Conclusions This study identified four metabolites that could possibly discriminate between AD and iNPH, which previous research has shown are closely related to the risk factors, pathogenesis, and symptoms of AD. Analyzing pathway-specific metabolites in the CSF of patients with AD may further elucidate the mechanism and pathogenesis of AD.
- Published
- 2018
- Full Text
- View/download PDF
20. Re-evaluation of soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders
- Author
-
Wataru Araki, Kotaro Hattori, Kazutomi Kanemaru, Yuma Yokoi, Yoshie Omachi, Harumasa Takano, Masuhiro Sakata, Sumiko Yoshida, Tadashi Tsukamoto, Miho Murata, Yuko Saito, Hiroshi Kunugi, Yu-ichi Goto, Utako Nagaoka, Masahiro Nagao, Takashi Komori, Kunimasa Arima, Kenji Ishii, Shigeo Murayama, Hiroshi Matsuda, Hisateru Tachimori, Yumiko M. Araki, and Hidehiro Mizusawa
- Subjects
Alzheimer’s disease ,Biomarker ,Cerebrospinal fluid ,Mild cognitive impairment ,Soluble amyloid precursor protein ,Tau ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Abstract Background Because soluble (or secreted) amyloid precursor protein-β (sAPPβ) and -α (sAPPα) possibly reflect pathological features of Alzheimer’s disease (AD), they are potential biomarker candidates for dementia disorders, including AD and mild cognitive impairment (MCI) due to AD (MCI-AD). However, controversial results have been reported regarding their alterations in the cerebrospinal fluid (CSF) of AD and MCI-AD patients. In this study, we re-assessed the utility of sAPPα and sAPPβ in CSF as diagnostic biomarkers of dementia disorders. Methods We used a modified and sensitive detection method to analyze sAPPs levels in CSF in four groups of patients: AD (N = 33), MCI-AD (N = 17), non-AD dementia (N = 27), and disease controls (N = 19). Phosphorylated tau (p-tau), total tau, and Aβ42 were also analyzed using standard methods. Results A strong correlation was observed between sAPPα and sAPPβ, consistent with previous reports. Both sAPPα and sAPPβ were highly correlated with p-tau and total tau, suggesting that sAPPs possibly reflect neuropathological changes in the brain. Levels of sAPPα were significantly higher in MCI-AD cases compared with non-AD and disease control cases, and those of sAPPβ were also significantly higher in MCI-AD and AD cases relative to other cases. A logistic regression analysis indicated that sAPPα and sAPPβ have good discriminative power for the diagnosis of MCI-AD. Conclusions Our findings collectively suggest that both sAPPs are pathologically relevant and potentially useful biomarkers for early and accurate diagnosis of dementia disorders. We also suggest that careful measurement is important in assessing the diagnostic utility of CSF sAPPs.
- Published
- 2017
- Full Text
- View/download PDF
21. Lysophosphatidic acid levels in cerebrospinal fluid and plasma samples in patients with major depressive disorder
- Author
-
Leo Gotoh, Misa Yamada, Kotaro Hattori, Daimei Sasayama, Takamasa Noda, Sumiko Yoshida, Hiroshi Kunugi, and Mitsuhiko Yamada
- Subjects
Psychiatry ,Neuroscience ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Major depressive disorder (MDD) is the most common psychiatric disorders. However, a biochemical marker has yet to be established for clinical purposes. It is proposed that lysophosphatidic acid (LPA, 1-acyl-2-sn-glycerol-3-phosphoate) plays some important roles in emotional regulation of experimental animals. Therefore, in this study, we measured LPA levels using enzyme-linked immunosorbent assays of cerebrospinal fluid (CSF) and plasma samples from patients with MDD. The participants were 52 patients and 49 normal healthy controls for CSF study, and 47 patients and 44 controls for plasma study. We used the Japanese version of the GRID Hamilton Depression Rating Scale (17-item version) for the assessment of depressive symptoms. We found no associations between LPA levels (CSF or plasma) and either diagnosis or severity of MDD, or with psychotropic medication. In conclusion, our data suggest that LPA levels likely would not serve as a practical biomarker of MDD.
- Published
- 2019
- Full Text
- View/download PDF
22. Bifidobacterium and Lactobacillus Counts in the Gut Microbiota of Patients With Bipolar Disorder and Healthy Controls
- Author
-
Emiko Aizawa, Hirokazu Tsuji, Takashi Asahara, Takuya Takahashi, Toshiya Teraishi, Sumiko Yoshida, Norie Koga, Kotaro Hattori, Miho Ota, and Hiroshi Kunugi
- Subjects
Bifidobacterium ,Lactobacillus ,bipolar disorder ,cortisol levels ,stress response ,Psychiatry ,RC435-571 - Abstract
Background: Although the pathophysiology of bipolar disorder remains elusive, growing evidence suggests the beneficial effects of Bifidobacterium and Lactobacillus in the gut microbiota on stress response and depressive symptoms. In the present study, we examined Bifidobacterium and Lactobacillus counts for association with bipolar disorder and serum cortisol levels.Methods: Bacterial counts in fecal samples were examined in 39 patients with bipolar disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edn. and 58 healthy controls using bacterial rRNA-targeted reverse transcription-quantitative polymerase chain reaction.Results: No significant difference was found in either bacterial counts between the two groups. However, we found a significantly negative correlation between Lactobacillus counts and sleep (ρ = −0.45, P = 0.01). Furthermore, a significant negative correlation was found between Bifidobacterium counts and cortisol levels (ρ = −0.39, P = 0.02) in the patients, although such a correlation was not found for Lactobacillus counts.Conclusions: Our results suggest that Bifidobacterium or Lactobacillus counts may not play a major role in the pathophysiology of bipolar disorder in our sample. However, the observed negative correlation between Lactobacillus counts and sleep and that between Bifidobacterium counts and serum cortisol levels point to the possible roles of these bacteria in sleep and stress response of the patients.
- Published
- 2019
- Full Text
- View/download PDF
23. Profiling of Cerebrospinal Fluid Lipids and Their Relationship with Plasma Lipids in Healthy Humans
- Author
-
Kosuke Saito, Kotaro Hattori, Shinsuke Hidese, Daimei Sasayama, Tomoko Miyakawa, Ryo Matsumura, Megumi Tatsumi, Yuuki Yokota, Miho Ota, Hiroaki Hori, and Hiroshi Kunugi
- Subjects
cerebrospinal fluid ,lipidomics ,lipid profiling ,mass spectrometry ,plasma lipid ,Microbiology ,QR1-502 - Abstract
Lipidomics provides an overview of lipid profiles in biological systems. Although blood is commonly used for lipid profiling, cerebrospinal fluid (CSF) is more suitable for exploring lipid homeostasis in brain diseases. However, whether an individual’s background affects the CSF lipid profile remains unclear, and the association between CSF and plasma lipid profiles in heathy individuals has not yet been defined. Herein, lipidomics approaches were employed to analyze CSF and plasma samples obtained from 114 healthy Japanese subjects. Results showed that the global lipid profiles differed significantly between CSF and plasma, with only 13 of 114 lipids found to be significantly correlated between the two matrices. Additionally, the CSF total protein content was the primary factor associated with CSF lipids. In the CSF, the levels of major lipids, namely, phosphatidylcholines, sphingomyelins, and cholesterolesters, correlated with CSF total protein levels. These findings indicate that CSF lipidomics can be applied to explore changes in lipid homeostasis in patients with brain diseases.
- Published
- 2021
- Full Text
- View/download PDF
24. Characterization of Postprandial Effects on CSF Metabolomics: A Pilot Study with Parallel Comparison to Plasma
- Author
-
Kosuke Saito, Kotaro Hattori, Tomohiro Andou, Yoshinori Satomi, Masamitsu Gotou, Hiroyuki Kobayashi, Shinsuke Hidese, and Hiroshi Kunugi
- Subjects
CSF metabolites ,metabolomics ,lipidomics ,postprandial effect ,Microbiology ,QR1-502 - Abstract
Cerebrospinal fluid (CSF) metabolites reflect biochemical diffusion/export from the brain and possibly serve as biomarkers related to brain disease severity, pathophysiology, and therapeutic efficacy/toxicity. Metabolomic studies using blood matrices have demonstrated interindividual and preanalytical variation of blood metabolites, whereas those of CSF metabolites remain unclear. In this study, we aimed to delineate the postprandial effects on CSF metabolites because fasting of patients with brain-related disorders is challenging. We collected pre- and postprandial (1.5, 3, and 6 h) plasma and CSF from nine healthy subjects. Using a mass-spectrometry-based global metabolomics approach, 150 and 130 hydrophilic metabolites and 263 and 340 lipids were detected in CSF and plasma, respectively. Principal component analysis of CSF hydrophilic metabolites and lipids primarily classified individual subjects at any time point, suggesting that the postprandial effects had a lower impact than interindividual variations on CSF metabolites. Individually, less than 10% of the CSF metabolites were putatively altered by postprandial effects (with either significant differences or over 2-fold changes, but not both) at any time point. Thus, global CSF metabolite levels are not directly associated with food intake, and except for several putatively altered CSF metabolites, postprandial effects are not a major concern when applying CSF metabolomics to screen biomarkers.
- Published
- 2020
- Full Text
- View/download PDF
25. Relationship of Handgrip Strength and Body Mass Index With Cognitive Function in Patients With Schizophrenia
- Author
-
Shinsuke Hidese, Junko Matsuo, Ikki Ishida, Moeko Hiraishi, Toshiya Teraishi, Miho Ota, Kotaro Hattori, and Hiroshi Kunugi
- Subjects
body mass index ,cognitive function ,handgrip strength ,schizophrenia ,physical activity ,Psychiatry ,RC435-571 - Abstract
Background: The relationship between muscle strength and cognition in schizophrenia has not been well studied. We investigated the potential relationship of handgrip strength (HGS) score and body mass index (BMI) with cognitive function in patients with schizophrenia.Methods: Participants included 153 patients with schizophrenia (age: 36.9 ± 9.4 years; 82 males) and 328 healthy controls (age: 36.4 ± 10.7 years; 150 males), matched for age, sex, and ethnicity (Japanese). HGS was measured using a digital handgrip dynamometer. Cognitive function was evaluated using the Brief Assessment of Cognition in Schizophrenia (BACS) test. A two-way multivariate analysis of covariance was used to compare HGS scores between the patient and control groups. Multiple regression analyses of BACS scores were performed in the patient and control groups using HGS and BMI scores as independent variables.Results: In the intergroup comparison, significantly lower HGS scores were observed in patients with schizophrenia than in healthy controls (p < 0.05, corrected). In the patient group, there was a significantly positive correlation between HGS scores and BACS composite score (male, p = 0.0014; female, p = 0.0051). However, BMI scores were significantly negatively correlated with the BACS composite score (male, p = 0.0022; female, p = 0.018). Furthermore, the ratio of HGS/BMI was significantly positively correlated with the BACS composite score in the patient group (p = 0.00000018).Conclusions: Cognitive function in patients with schizophrenia is correlated positively with HGS and negatively with BMI. HGS/BMI may thus be a good index for cognitive performance in schizophrenia.
- Published
- 2018
- Full Text
- View/download PDF
26. Plasma Metabolites Predict Severity of Depression and Suicidal Ideation in Psychiatric Patients-A Multicenter Pilot Analysis.
- Author
-
Daiki Setoyama, Takahiro A Kato, Ryota Hashimoto, Hiroshi Kunugi, Kotaro Hattori, Kohei Hayakawa, Mina Sato-Kasai, Norihiro Shimokawa, Sachie Kaneko, Sumiko Yoshida, Yu-Ichi Goto, Yuka Yasuda, Hidenaga Yamamori, Masahiro Ohgidani, Noriaki Sagata, Daisuke Miura, Dongchon Kang, and Shigenobu Kanba
- Subjects
Medicine ,Science - Abstract
Evaluating the severity of depression (SOD), especially suicidal ideation (SI), is crucial in the treatment of not only patients with mood disorders but also psychiatric patients in general. SOD has been assessed on interviews such as the Hamilton Rating Scale for Depression (HAMD)-17, and/or self-administered questionnaires such as the Patient Health Questionnaire (PHQ)-9. However, these evaluation systems have relied on a person's subjective information, which sometimes lead to difficulties in clinical settings. To resolve this limitation, a more objective SOD evaluation system is needed. Herein, we collected clinical data including HAMD-17/PHQ-9 and blood plasma of psychiatric patients from three independent clinical centers. We performed metabolome analysis of blood plasma using liquid chromatography mass spectrometry (LC-MS), and 123 metabolites were detected. Interestingly, five plasma metabolites (3-hydroxybutyrate (3HB), betaine, citrate, creatinine, and gamma-aminobutyric acid (GABA)) are commonly associated with SOD in all three independent cohort sets regardless of the presence or absence of medication and diagnostic difference. In addition, we have shown several metabolites are independently associated with sub-symptoms of depression including SI. We successfully created a classification model to discriminate depressive patients with or without SI by machine learning technique. Finally, we produced a pilot algorithm to predict a grade of SI with citrate and kynurenine. The above metabolites may have strongly been associated with the underlying novel biological pathophysiology of SOD. We should explore the biological impact of these metabolites on depressive symptoms by utilizing a cross species study model with human and rodents. The present multicenter pilot study offers a potential utility for measuring blood metabolites as a novel objective tool for not only assessing SOD but also evaluating therapeutic efficacy in clinical practice. In addition, modification of these metabolites by diet and/or medications may be a novel therapeutic target for depression. To clarify these aspects, clinical trials measuring metabolites before/after interventions should be conducted. Larger cohort studies including non-clinical subjects are also warranted to clarify our pilot findings.
- Published
- 2016
- Full Text
- View/download PDF
27. Discrepancy between Clinician-rated and Self-reported Depression Severity is Associated with Adverse Childhood Experience, Autistic-like Traits, and Coping Styles in Mood Disorders
- Author
-
Risa Yamada, Takeshi Fujii, Kotaro Hattori, Hiroaki Hori, Ryo Matsumura, Tomoko Kurashimo, Naoko Ishihara, Sumiko Yoshida, Tomiki Sumiyoshi, and Hiroshi Kunugi
- Subjects
Behavioral Neuroscience ,Psychiatry and Mental health ,Pharmacology (medical) - Published
- 2023
28. Association between the Pittsburgh sleep quality index and white matter integrity in healthy adults: a whole-brain magnetic resonance imaging study
- Author
-
Shinsuke Hidese, Miho Ota, Junko Matsuo, Ikki Ishida, Yuuki Yokota, Kotaro Hattori, Yukihito Yomogida, and Hiroshi Kunugi
- Subjects
Neuropsychology and Physiological Psychology ,Neurology ,Physiology ,Physiology (medical) - Published
- 2023
29. Shell-like structure to limit further densification formed during flash sintering under alternative current electric field for 8 mol %Y2O3-doped ZrO2
- Author
-
Mikito Seko, Kotaro Hattori, Yuki Ishino, Ayu Kodaira, Tomoharu Tokunaga, and Takahisa Yamamoto
- Subjects
Materials Chemistry ,Ceramics and Composites ,General Chemistry ,Condensed Matter Physics - Published
- 2022
30. Haplotype phasing of a bipolar disorder pedigree revealed rare multiple mutations of SPOCD1 gene in the 1p36–35 susceptibility locus
- Author
-
Gakuya Takamatsu, Kumiko Yanagi, Kae Koganebuchi, Fuyuko Yoshida, Jun-Seok Lee, Kanako Toyama, Kotaro Hattori, Chiaki Katagiri, Tsuyoshi Kondo, Hiroshi Kunugi, Ryosuke Kimura, Tadashi Kaname, and Masayuki Matsushita
- Subjects
Psychiatry and Mental health ,Clinical Psychology ,Bipolar Disorder ,Haplotypes ,Chromosomes, Human, Pair 1 ,Mutation ,Humans ,Genetic Predisposition to Disease ,Proteoglycans ,Polymorphism, Single Nucleotide ,Genome-Wide Association Study ,Pedigree - Abstract
The etiology of bipolar disorder (BD) is poorly understood. Considering the complexity of BD, pedigree-based sequencing studies focusing on haplotypes at specific loci may be practical to discover high-impact risk variants. This study comprehensively examined the haplotype sequence at 1p36-35 BD and recurrent depressive disorder (RDD) susceptibility loci.We surveyed BD families in Okinawa, Japan. We performed linkage analysis and determined the phased sequence of the affected haplotype using whole genome sequencing. We filtered rare missense variants on the haplotype. For validation, we conducted a case-control genetic association study on approximately 3000 Japanese subjects.We identified a three-generation multiplex pedigree with BD and RDD. Strikingly, we identified a significant linkage with mood disorders (logarithm of odds [LOD] = 3.61) at 1p36-35, supported in other ancestry studies. Finally, we determined the entire sequence of the 6.4-Mb haplotype shared by all affected subjects. Moreover, we found a rare triplet of missense variants in the SPOCD1 gene on the haplotype. Notably, despite the rare frequency, one heterozygote with multiple SPOCD1 variants was identified in an independent set of 88 BD type I genotyping samples.The 1p36-35 sequence was obtained from only a single pedigree. The replicate sample was small. Short-read sequencing might miss structural variants. A polygenic risk score was not analyzed.The 1p36-35 haplotype sequence may be valuable for future BD variant studies. In particular, SPOCD1 is a promising candidate gene and should be validated.
- Published
- 2022
31. Brain-Derived Major Glycoproteins Are Possible Biomarkers for Altered Metabolism of Cerebrospinal Fluid in Neurological Diseases
- Author
-
Kyoka Hoshi, Mayumi Kanno, Aya Goto, Yoshikazu Ugawa, Katsutoshi Furukawa, Hiroyuki Arai, Masakazu Miyajima, Koichi Takahashi, Kotaro Hattori, Keiichi Kan, Takashi Saito, Yoshiki Yamaguchi, Takashi Mitsufuji, Nobuo Araki, and Yasuhiro Hashimoto
- Subjects
Inorganic Chemistry ,Organic Chemistry ,General Medicine ,cerebrospinal fluid ,choroid plexus ,neuron ,prostaglandin D2 synthase ,brain-derived transferrin ,neurological diseases ,Physical and Theoretical Chemistry ,Molecular Biology ,Spectroscopy ,Catalysis ,Computer Science Applications - Abstract
Cerebrospinal fluid (CSF) plays an important role in the homeostasis of the brain. We previously reported that CSF major glycoproteins are biosynthesized in the brain, i.e., lipocalin-type prostaglandin D2 synthase (L-PGDS) and transferrin isoforms carrying unique glycans. Although these glycoproteins are secreted from distinct cell types, their CSF levels have been found to be highly correlated with each other in cases of neurodegenerative disorders. The aim of this study was to examine these marker levels and their correlations in other neurological diseases, such as depression and schizophrenia, and disorders featuring abnormal CSF metabolism, including spontaneous intracranial hypotension (SIH) and idiopathic normal pressure hydrocephalus (iNPH). Brain-derived marker levels were found to be highly correlated with each other in the CSF of depression and schizophrenia patients. SIH is caused by CSF leakage, which is suspected to induce hypovolemia and a compensatory increase in CSF production. In SIH, the brain-derived markers were 2–3-fold higher than in other diseases, and, regardless of their diverse levels, they were found to be correlated with each other. Another abnormality of the CSF metabolism, iNPH, is possibly caused by the reduced absorption of CSF, which secondarily induces CSF accumulation in the ventricle; the excess CSF compresses the brain’s parenchyma to induce dementia. One potential treatment is a “shunt operation” to bypass excess CSF from the ventricles to the peritoneal cavity, leading to the attenuation of dementia. After the shunt operation, marker levels began to increase within a week and then further increased by 2–2.5-fold at three, six, and twelve months post-operation, at which point symptoms had gradually attenuated. Notably, the marker levels were found to be correlated with each other in the post-operative period. In conclusion, the brain-derived major glycoprotein markers were highly correlated in the CSF of patients with different neurological diseases, and their correlations were maintained even after surgical intervention. These results suggest that brain-derived proteins could be biomarkers of CSF production.
- Published
- 2023
- Full Text
- View/download PDF
32. Association between vascular endothelial growth factor-mediated blood–brain barrier dysfunction and stress-induced depression
- Author
-
Hitomi Matsuno, Shoko Tsuchimine, Kazunori O’Hashi, Kazuhisa Sakai, Kotaro Hattori, Shinsuke Hidese, Shingo Nakajima, Shuichi Chiba, Aya Yoshimura, Noriko Fukuzato, Mayumi Kando, Megumi Tatsumi, Shintaro Ogawa, Noritaka Ichinohe, Hiroshi Kunugi, and Kazuhiro Sohya
- Subjects
Vascular Endothelial Growth Factor A ,Capillary Permeability ,Mice ,Depressive Disorder, Major ,Brain Diseases ,Mice, Inbred BALB C ,Cellular and Molecular Neuroscience ,Psychiatry and Mental health ,Blood-Brain Barrier ,Depression ,Animals ,Endothelial Cells ,Molecular Biology - Abstract
Several lines of evidence suggest that stress induces the neurovascular dysfunction associated with increased blood-brain barrier (BBB) permeability, which could be an important pathology linking stress and psychiatric disorders, including major depressive disorder (MDD). However, the detailed mechanism resulting in BBB dysfunction associated in the pathophysiology of MDD still remains unclear. Herein, we demonstrate the role of vascular endothelial growth factor (VEGF), a key mediator of vascular angiogenesis and BBB permeability, in stress-induced BBB dysfunction and depressive-like behavior development. We implemented an animal model of depression, chronic restraint stress (RS) in BALB/c mice, and found that the BBB permeability was significantly increased in chronically stressed mice. Immunohistochemical and electron microscopic observations revealed that increased BBB permeability was associated with both paracellular and transcellular barrier alterations in the brain endothelial cells. Pharmacological inhibition of VEGF receptor 2 (VEGFR2) using a specific monoclonal antibody (DC101) prevented chronic RS-induced BBB permeability and anhedonic behavior. Considered together, these results indicate that VEGF/VEGFR2 plays a crucial role in the pathogenesis of depression by increasing the BBB permeability, and suggest that VEGFR2 inhibition could be a potential therapeutic strategy for the MDD subtype associated with BBB dysfunction.
- Published
- 2022
33. Reduced homovanillic acid, SDF-1α and SCGF-β levels in cerebrospinal fluid are related to depressive states in systemic lupus erythematosus
- Author
-
Yuya Fujita, Shigeru Iwata, Shinsuke Hidese, Sayuri Ishiwata, Satoru Ide, Hiroaki Tanaka, Koshiro Sonomoto, Yusuke Miyazaki, Shingo Nakayamada, Atsuko Ikenouchi, Kotaro Hattori, Hiroshi Kunugi, Reiji Yoshimura, and Yoshiya Tanaka
- Subjects
Rheumatology ,Pharmacology (medical) - Abstract
ObjectiveThis study aimed to seek a new method of evaluation and surrogate markers for diffuse neuropsychiatric SLE (NPSLE).MethodsWe enrolled 44 patients with SLE between 2017 and 2020 who fulfilled at least one of three specific inclusion criteria: high disease activity, abnormal findings (cerebrospinal fluid [CSF] examination, brain MRI, or electroencephalography), or history of neuropsychiatric illness. Psychiatric symptom rating scales (PSYRATS) were evaluated retrospectively. The primary end point was the PSYRATS positivity rate in SLE patients who had not been diagnosed with diffuse NPSLE.ResultsBased on the 1999 ACR classifications, 7 out of the 44 patients evaluated using PSYRATS had been diagnosed with diffuse NPSLE. PSYRATS positivity was seen in 13 out of 37 SLE patients (35.1%) who had not been diagnosed with diffuse NPSLE, and all these patients were positive for Montgomery–Åsberg Depression Rating Scale (MADRS), an indicator of depression state in PSYRATS. Additionally, in the 20 SLE patients exhibiting depression symptoms who were MADRS-positive, CSF concentrations of the neuroinflammatory markers homovanillic acid (HVA; P = 0.0400), stromal cell-derived factor-1α (SDF-1α; P = 0.0431) and stem cell growth factor-β (SCGF-1β; P = 0.0061) were significantly reduced compared with the 24 MADRS-negative SLE patients, and the levels of HVA, SDF-1α and SCGF-1β correlated with one another (P ConclusionMany patients with active SLE have subclinical depression, and MADRS evaluation of neuropsychiatric symptoms is useful for detecting them. Additionally, the decrease in CSF levels of HVA, SDF-1 α and SCGF-1β reflects the same pathology, and these may serve as surrogate markers.
- Published
- 2023
34. Plasma neuropeptide levels in patients with schizophrenia, bipolar disorder, or major depressive disorder and healthy controls: A multiplex immunoassay study
- Author
-
Shinsuke Hidese, Fuyuko Yoshida, Ikki Ishida, Junko Matsuo, Kotaro Hattori, and Hiroshi Kunugi
- Subjects
Pharmacology ,Psychiatry and Mental health ,Clinical Psychology ,Pharmacology (medical) - Abstract
We aimed to compare neuropeptide levels between patients with major psychiatric disorders and healthy controls and examine their association with symptoms and cognitive function.The participants were 149 patients with schizophrenia, 115 patients with bipolar disorder (BD), 186 unremitted patients with major depressive disorder (MDD), and 350 healthy controls. Psychiatric (schizophrenic, manic, and depressive) symptoms, sleep state, and cognitive (premorbid intelligence quotient, general cognitive, and memory) functions were evaluated. A multiplex immunoassay kit was used to measure cerebrospinal fluid (CSF) and plasma α-melanocyte-stimulating hormone (MSH), β-endorphin, neurotensin, oxytocin, and substance P levels.The verification assay revealed that CSF α-MSH, β-endorphin, neurotensin, oxytocin, and substance P levels were too low to be reliably measured, while plasma α-MSH, β-endorphin, neurotensin, oxytocin, and substance P levels could be successfully measured. Plasma α-MSH, β-endorphin, neurotensin, oxytocin, and substance P levels were not significantly different between patients with schizophrenia, BD, or MDD and healthy controls. Plasma α-MSH, β-endorphin, neurotensin, oxytocin, and substance P levels were not significantly correlated with psychiatric symptom scores in patients with schizophrenia, BD, or MDD and cognitive function scores in patients or healthy controls.Our data suggest that plasma neuropeptide levels do not elucidate the involvement of neuropeptides in the pathology of schizophrenia, BD, or MDD.
- Published
- 2022
35. Soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for differential diagnosis of mild cognitive impairment
- Author
-
Kotaro Hattori, Wataru Araki, Yuma Yokoi, Yuko Saito, Kazutomi Kanemaru, Masuhiro Sakata, Hisateru Tachimori, Shigeo Murayama, Yoshie Omachi, Harumasa Takano, Hidehiro Mizusawa, Masahiro Nagao, Takashi Komori, Tadashi Tsukamoto, Sumiko Yoshida, and Utako Nagaoka
- Subjects
Aging ,medicine.medical_specialty ,Amyloid ,tau Proteins ,Neuropathology ,behavioral disciplines and activities ,Diagnosis, Differential ,Amyloid beta-Protein Precursor ,Cerebrospinal fluid ,Alzheimer Disease ,Internal medicine ,mental disorders ,medicine ,Humans ,Cognitive Dysfunction ,Cognitive impairment ,Amyloid beta-Peptides ,business.industry ,Control subjects ,Peptide Fragments ,Endocrinology ,Potential biomarkers ,Biomarker (medicine) ,Geriatrics and Gerontology ,Differential diagnosis ,business ,human activities ,Biomarkers - Abstract
Concentrations of soluble amyloid precursor proteins-α (sAPPα) and -β (sAPPβ) in cerebrospinal fluid (CSF) may reflect the neuropathology of Alzheimer’s disease (AD). We previously reported that the concentrations of both sAPPα and sAPPβ were significantly higher in patients with mild cognitive impairment (MCI) due to AD (MCI-AD) than in control subjects without cognitive impairment. The present study analyzed whether these sAPPs are useful in the differential diagnosis of MCI. A modified and sensitive method was used to analyze concentrations of sAPPα and sAPPβ in CSF of patients with MCI-AD (n = 30) and MCI due to other causes (MCI-others) (n = 24). Phosphorylated tau (p-tau) and amyloid β-protein 42 (Aβ42) were also analyzed using standard methods. CSF concentrations of sAPPα and sAPPβ were significantly higher in the MCI-AD than in the MCI-others group (p
- Published
- 2021
36. Reduced Cerebrospinal Fluid Levels of Lysophosphatidic Acid Docosahexaenoic Acid in Patients With Major Depressive Disorder and Schizophrenia
- Author
-
Junken Aoki, Kotaro Hattori, Mami Tsuchioka, Hiroshi Kunugi, Minoru Takebayashi, Wataru Omori, Kuniyuki Kano, Shuken Boku, and Naoto Kajitani
- Subjects
Male ,0301 basic medicine ,Regular Research Articles ,chemistry.chemical_compound ,0302 clinical medicine ,Cerebrospinal fluid ,Japan ,Lysophosphatidic acid ,Pharmacology (medical) ,AcademicSubjects/SCI01870 ,Middle Aged ,docosahexaenoic acid ,Pathophysiology ,Psychiatry and Mental health ,Docosahexaenoic acid ,Schizophrenia ,Major depressive disorder ,Female ,lipids (amino acids, peptides, and proteins) ,biological phenomena, cell phenomena, and immunity ,medicine.symptom ,Autotaxin ,Adult ,medicine.medical_specialty ,Docosahexaenoic Acids ,AcademicSubjects/MED00415 ,Inflammation ,behavioral disciplines and activities ,03 medical and health sciences ,Internal medicine ,mental disorders ,medicine ,Humans ,Pharmacology ,Depressive Disorder, Major ,major depressive disorder ,Phosphoric Diester Hydrolases ,business.industry ,medicine.disease ,schizophrenia ,030104 developmental biology ,Endocrinology ,chemistry ,Case-Control Studies ,Lysophospholipids ,business ,lysophosphatidic acid ,030217 neurology & neurosurgery ,Chromatography, Liquid - Abstract
Background Lysophosphatidic acid (LPA) is involved in numerous biological processes, including neurodevelopment, chronic inflammation, and immunologic response in the central nervous system. Autotaxin (ATX) is a secreted enzyme that produces LPA from lysophosphatidylcholine (LPC). Previous studies have demonstrated decreased protein levels of ATX in cerebrospinal fluid (CSF) of patients with major depressive disorder (MDD). Based on those studies, the current study investigated the levels of lysophospholipids species including LPA and related metabolic enzymes, in CSF of patients with MDD and schizophrenia (SCZ). Methods The levels of lysophospholipids species and related metabolic enzymes were measured with either liquid chromatography-tandem mass spectrometry or enzyme-linked immunosorbent assay. Japanese patients were diagnosed with DSM-IV-TR. CSF was obtained from age- and sex-matched healthy controls (n = 27) and patients with MDD (n = 26) and SCZ (n = 27). Results Of all lysophospholipids species, the levels of LPA 22:6 (LPA - docosahexaenoic acid) were significantly lower in patients with MDD and SCZ than in healthy controls. These levels were negatively correlated with several clinical symptomatic scores of MDD, but not those of SCZ. In addition, the levels of LPA 22:6 were significantly correlated with the levels of LPC 22:6 among all 3 groups. On the other hand, the levels of LPA 22:6 were not correlated with ATX activity in patients with MDD and SCZ. Conclusion The lower levels of LPA 22:6 in patients with MDD and SCZ suggest an abnormality of LPA 22:6 metabolism. In addition, several depressive symptoms in patients with MDD were significantly associated with the lower levels of LPA 22:6, suggesting an involvement of LPA 22:6 in the pathophysiology of MDD.
- Published
- 2021
37. BMP4-SMAD1/5/9-RUNX2 pathway activation inhibits neurogenesis and oligodendrogenesis in Alzheimer’s patients’ iPSCs in senescence-related conditions
- Author
-
Daiki Nakatsu, Rina Kunishige, Yuki Taguchi, Naeko Shinozaki-Narikawa, Kishiko Osaka, Kayo Yokomizo, Mami Ishida, Shunsuke Takei, Shoko Yamasaki, Keita Hagiya, Kotaro Hattori, Tadashi Tsukamoto, Masayuki Murata, and Fumi Kano
- Subjects
Genetics ,Cell Biology ,Biochemistry ,Developmental Biology - Published
- 2023
38. Platelet-derived growth factor BB: A potential diagnostic blood biomarker for differentiating bipolar disorder from major depressive disorder
- Author
-
Kazuyuki Nakagome, Kiyomitsu Ota, Kotaro Hattori, Hidenaga Yamamori, Sumiko Yoshida, Ryota Hashimoto, Yosuke Kameno, Akitoyo Hishimoto, Kenji Hashimoto, Yasunori Oda, Mitsuru Kikuchi, Shigenobu Toda, Yoshio Minabe, Norio Mori, Ikuo Otsuka, Keita Idemoto, Tatsuki Hata, Tasuku Hashimoto, Atsushi Kimura, Masaomi Iyo, Tomihisa Niitsu, Tamaki Ishima, and Tadasu Horai
- Subjects
medicine.medical_specialty ,Bipolar Disorder ,Becaplermin ,Young Mania Rating Scale ,behavioral disciplines and activities ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Rating scale ,Internal medicine ,mental disorders ,medicine ,Humans ,Bipolar disorder ,Biological Psychiatry ,Depression (differential diagnoses) ,Depressive Disorder, Major ,business.industry ,Confounding ,medicine.disease ,030227 psychiatry ,Psychiatry and Mental health ,Cross-Sectional Studies ,Case-Control Studies ,Biomarker (medicine) ,Major depressive disorder ,business ,Body mass index ,Biomarkers ,030217 neurology & neurosurgery - Abstract
Bipolar disorder (BD) is frequently misdiagnosed as major depressive disorder (MDD) due to overlapping depressive symptoms. This study investigated whether serum platelet-derived growth factor BB (PDGF-BB) is a differential diagnostic biomarker for BD and MDD. An initial SOMAscan proteomics assay of 1311 proteins in small samples from patients with BD and MDD and healthy controls (HCs) suggested that serum levels of PDGF-BB differed between BD and MDD. We then conducted a two-step, exploratory, cross-sectional, case–control study at our institute and five sites that included a total of 549 participants (157 with BD, 144 with MDD, and 248 HCs). Clinical symptoms were assessed using the Hamilton Depression Rating Scale and the Young Mania Rating Scale. In the initial analysis at our institute, serum PDGF-BB levels in the MDD group (n = 36) were significantly lower than those in the BD (n = 39) and HC groups (n = 36). In the multicenter study, serum PDGF-BB levels in the MDD group were again significantly lower than those in the BD and HC groups, with no significant difference between the BD and HC groups. Treatment with sodium valproate was associated with significantly lower serum PDGF-BB levels in patients with BD. After controlling for confounding factors (sex, age, body mass index, clinical severity, and valproate medication), serum PDGF-BB levels were lower in the MDD group than in the BD group regardless of mood state. Our findings suggest that serum PDGF-BB may be a potential biomarker to differentiate BD and MDD.
- Published
- 2021
39. Lower cerebrospinal fluid CRH concentration in chronic schizophrenia with negative symptoms
- Author
-
Hiroshi Kunugi, Tomoko Miyakawa, Sayuri Ishiwata, Daimei Sasayama, Shinsuke Hidese, Sumiko Yoshida, Kotaro Hattori, Ryo Matsumura, and Yuuki Yokota
- Subjects
Hypothalamo-Hypophyseal System ,endocrine system ,medicine.medical_specialty ,Hydrocortisone ,Corticotropin-Releasing Hormone ,medicine.medical_treatment ,Pituitary-Adrenal System ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Cerebrospinal fluid ,Internal medicine ,Humans ,Medicine ,Antipsychotic ,Chlorpromazine ,Biological Psychiatry ,medicine.diagnostic_test ,Positive and Negative Syndrome Scale ,business.industry ,Lumbar puncture ,medicine.disease ,030227 psychiatry ,Psychiatry and Mental health ,Schizophrenia ,Population study ,business ,hormones, hormone substitutes, and hormone antagonists ,030217 neurology & neurosurgery ,Antipsychotic Agents ,Diagnosis of schizophrenia ,medicine.drug - Abstract
Some patients with schizophrenia have impaired hypothalamic-pituitary-adrenal axis function. However, there is a dearth of studies focusing on corticotropin-releasing hormone (CRH) levels in the brains of schizophrenia patients, which motivated us to examine whether cerebrospinal fluid (CSF) CRH concentrations are altered in these patients. We also examined the possible correlation of CSF CRH level with clinical variables such as schizophrenia symptoms and antipsychotic medication. The study population comprised 20 patients with a diagnosis of schizophrenia according to DSM-5 criteria and 25 healthy controls, who underwent lumbar puncture. Most of the patients were treated with antipsychotic drugs and their doses were converted to chlorpromazine (CP) equivalent values. CSF CRH concentrations were measured by an enzyme immunoassay. Symptom severity was assessed using the Positive and Negative Syndrome Scale (PANSS). There was a significantly lower CSF CRH concentration in the patients than in the controls (Mann-Whitney U test: p = 0.014). A significantly negative correlation of CSF CRH levels with PANSS negative scores was found in the patients (Spearman's: ρ = −0.58, p = 0.007). However, CSF CRH concentrations were not significantly correlated with the PANSS total (ρ = −0.035, p = 0.89), positive (ρ = 0.25, p = 0.30), or general psychopathology (ρ = 0.13, p = 0.59) scores. No significant correlation was found with CP equivalent values (ρ = 0.00, p = 1.00). In conclusion, we found that the patients with schizophrenia had lower CSF CRH concentrations compared to the controls and that the lower CSF CRH was associated with negative symptoms of the illness. Further studies in a larger sample and in drug-free patients are warranted.
- Published
- 2020
40. Dry sliding wear resistance characterization of titanium matrix composites reinforced with titanium carbonitrides
- Author
-
Kotaro Hattori, Hiroshi Izui, and Yoshiki Komiya
- Subjects
pure titanium ,Materials science ,chemistry.chemical_element ,ti-6al-4v alloy ,Characterization (materials science) ,tic0.3n0.7 ,titanium carbonitrides (tic1-xnx) ,chemistry ,titanium matrix composites ,Titanium matrix composites ,tic0.7n0.3 ,TJ1-1570 ,dry sliding wear resistance ,Ti 6al 4v ,Mechanical engineering and machinery ,Composite material ,Sliding wear ,Titanium - Abstract
Pure Ti and Ti-6Al-4V alloy show high specific strength, excellent fatigue strength and good corrosion resistance; however, their poor wear resistance limits potentially wider application. To improve the wear resistance of pure Ti and Ti-6Al-4V alloy, they were reinforced with two types of titanium carbonitrides (TiC1-xNx), TiC0.3N0.7 (N rich) and TiC0.7N0.3 (C rich). The composites with 2.5, 5.0, 7.5 and 10.0 vol.% reinforcement were fabricated by spark plasma sintering (SPS). Dry wear tests of the composites were performed against a 10 mm-diameter high-carbon-chromium steel ball under 23 N normal load, at a sliding speed of 100 mm/s and a sliding distance of 500 m using a ball-on-disk configuration. The pure Ti and Ti-6Al-4V alloy matrix composites with TiC0.3N0.7 showed good wear resistance compared to the composites with TiC0.7N0.3. For the TiC0.3N0.7 reinforcement, the pure Ti matrix composite showed better wear resistance than the Ti-6Al-4V alloy matrix composite. The specific wear rate of the pure Ti matrix composite containing 10 vol.% TiC0.3N0.7 was almost zero. The amount of nitrogen diffused into the titanium matrix was higher than that of carbon diffused into the matrix. The Vickers hardnesses of the composites with TiC0.3N0.7 were higher than those of the composites with TiC0.7N0.3, due to the solid solution strengthening of the nitrogen in the Ti matrix. Therefore, the dry sliding wear characteristics of the titanium matrix composites depended on the amount of nitrogen diffused into the Ti matrix.
- Published
- 2020
41. Increased Matrix Metalloproteinases in Cerebrospinal Fluids of Patients With Major Depressive Disorder and Schizophrenia
- Author
-
Yasumasa Okamoto, Naoto Kajitani, Hiroshi Kunugi, Minoru Takebayashi, Wataru Omori, Kotaro Hattori, Shuken Boku, and Mami Tsuchioka
- Subjects
AcademicSubjects/MED00415 ,Inflammation ,Matrix metalloproteinase ,Regular Research Articles ,behavioral disciplines and activities ,cerebrospinal fluid ,Cerebrospinal fluid ,mental disorders ,medicine ,Pharmacology (medical) ,Pharmacology ,brain inflammation ,major depressive disorder ,Positive and Negative Syndrome Scale ,AcademicSubjects/SCI01870 ,business.industry ,Hamilton Rating Scale for Depression ,medicine.disease ,Pathophysiology ,schizophrenia ,Psychiatry and Mental health ,Matrix metalloproteinases ,Schizophrenia ,Immunology ,Major depressive disorder ,medicine.symptom ,business - Abstract
Background Chronic inflammation of the brain has a pivotal role in the pathophysiology of major depressive disorder (MDD) and schizophrenia (SCZ). Matrix metalloproteinases (MMPs) are extracellular proteases involved in pro-inflammatory processes and interact with interleukin-6, which is increased in the cerebrospinal fluid (CSF) of patients with MDD and SCZ. However, MMPs in the CSF in patients with MDD and SCZ remain unclear. Therefore, we compared MMPs in the CSF of patients with MDD and SCZ with those of healthy controls (HC). Methods Japanese patients were diagnosed with DSM-IV-TR and clinical symptoms were assessed with the Hamilton Rating Scale for Depression for MDD and the Positive and Negative Syndrome Scale for SCZ. CSF was obtained from MDD (n = 90) and SCZ (n = 86) and from age- and sex-matched HC (n = 106). The levels of MMPs in CSF were measured with multiplex bead-based immunoassay. Results The levels of MMP-2 in CSF were higher in both MDD and SCZ than HC and were positively correlated with clinical symptomatic scores in MDD, but not in SCZ. Regardless of diagnosis, the levels of MMP-2, -7, and -10 were positively correlated with each other, and the levels of MMP-7 and -10 were higher in MDD, but not in SCZ, compared with HC. Conclusion Increased CSF levels of MMP-2 in MDD and SCZ may be associated with brain inflammation. State-dependent alteration of MMP-2 and activation of cascades involving MMP-2, -7, and -10 appeared to have a role in the pathophysiology of MDD.
- Published
- 2020
42. Investigating DNA Methylation of SHATI/NAT8L Promoter Sites in Blood of Unmedicated Patients with Major Depressive Disorder
- Author
-
Hajime Miyanishi, Kyosuke Uno, Yu-ichi Goto, Sumiko Yoshida, Kotaro Hattori, Tomiki Sumiyoshi, Mina Iwata, Yuu Kikuchi, Yuka Yasuda, Ryota Hashimoto, Atsumi Nitta, Kazutaka Ohi, and Hidenaga Yamamori
- Subjects
0301 basic medicine ,Pharmacology ,Oncology ,medicine.medical_specialty ,business.industry ,Pharmaceutical Science ,Promoter ,General Medicine ,Methylation ,medicine.disease ,behavioral disciplines and activities ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,CpG site ,030220 oncology & carcinogenesis ,Internal medicine ,mental disorders ,DNA methylation ,Medicine ,Biomarker (medicine) ,Major depressive disorder ,Pyrosequencing ,business ,Gene - Abstract
Major depressive disorder (MDD) is one of the most common psychiatric diseases. However, early detection and diagnosis of MDD is difficult, largely because there is no known biomarker or objective diagnostic examination, and its diagnosis is instead based on a clinical interview. The aim of this study was to develop a novel diagnostic tool using DNA methylation as a blood biomarker. We sought to determine whether unmedicated patients with MDD showed significant differences in DNA methylation in the promoter region of the SHATI/N-acetyltransferase 8 like (SHATI/NAT8L) gene compared to healthy controls. Sixty participants with MDD were recruited from all over Japan. They were diagnosed and assessed by at least two trained psychiatrists according to DSM-5 criteria. DNA was extracted from peripheral blood. We then assessed DNA methylation of the SHATI/NAT8L promoter regions in patients with MDD by pyrosequencing. Methylation levels of the SHATI/NAT8L promoter region at CpG sites in peripheral blood from unmedicated patients were significantly higher than in healthy controls. In contrast, medicated patients with MDD showed significantly lower methylation levels in the same region compared to healthy controls. Since previous studies of DNA methylation in MDD only assessed medicated patients, the methylation status of the SHATI/NAT8L promoter region in unmedicated patients presented herein may prove useful for the diagnosis of MDD. To our knowledge, this is the first attempt to measure methylation of the SHATI/NAT8L gene in drug-naive patients with psychiatric diseases. Based on our findings, methylation of SHATI/NAT8L DNA might be a diagnostic biomarker of MDD.
- Published
- 2020
43. Increased apolipoprotein E and decreased TNF‐α in the cerebrospinal fluid of nondemented APOE‐ε4 carriers
- Author
-
Ryo Matsumura, Sumiko Yoshida, Daimei Sasayama, Kotaro Hattori, Hiroshi Kunugi, Toshiya Teraishi, and Yuuki Yokota
- Subjects
Apolipoprotein E ,Adult ,Male ,medicine.medical_specialty ,Heterozygote ,Apolipoprotein E4 ,cerebrospinal fluid proteins ,Pathogenesis ,Micro Report ,Cerebrospinal fluid ,Japan ,Internal medicine ,alzheimer disease ,Medicine ,Dementia ,Humans ,Pharmacology (medical) ,Allele ,Risk factor ,Pharmacology ,business.industry ,Tumor Necrosis Factor-alpha ,biomarkers ,Middle Aged ,medicine.disease ,tumor necrosis factor‐alpha ,Psychiatry and Mental health ,Clinical Psychology ,Endocrinology ,Tumor necrosis factor alpha ,lipids (amino acids, peptides, and proteins) ,Female ,Alzheimer's disease ,business ,apolipoproteins E - Abstract
Aim The ε4 allele of apolipoprotein E gene (APOE) is a well‐known risk factor of late‐onset Alzheimer's disease. However, little is known why this variant confers a risk for Alzheimer's disease. The aim of this study was to examine the influence of the APOE genotype on cerebrospinal fluid (CSF) protein levels. Methods The present study performed a secondary analysis on our previously generated database to compare the CSF levels of 1128 proteins between APOE‐ε4 carriers (28 subjects) and noncarriers (104 subjects). All subjects were physically healthy Japanese individuals without dementia. Results CSF levels of apoE2, apoE3, and apoE4 were significantly higher (all nominal P, The CSF levels of apoE2, apoE3, and apoE4 were higher in APOE‐ε4 carriers. The CSF levels of TNF‐α were significantly lower in APOE‐ε4 carriers. Our findings indicate the possible roles of apoE and TNF‐α in the pathogenesis of APOE‐ε4‐associated Alzheimer's disease.
- Published
- 2020
44. Cerebrospinal fluid neuroplasticity-associated protein levels in patients with psychiatric disorders: a multiplex immunoassay study
- Author
-
Kotaro Hattori, Yuuki Yokota, Junko Matsuo, Ryo Matsumura, Miho Ota, Tomoko Miyakawa, Takuya Tsumagari, Sumiko Yoshida, Hiroshi Kunugi, Ikki Ishida, Daimei Sasayama, and Shinsuke Hidese
- Subjects
medicine.medical_specialty ,Bipolar Disorder ,Molecular neuroscience ,Article ,lcsh:RC321-571 ,Cellular and Molecular Neuroscience ,Cerebrospinal fluid ,Neurotrophic factors ,mental disorders ,Glial cell line-derived neurotrophic factor ,Medicine ,Humans ,Bipolar disorder ,Psychiatry ,lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry ,Biological Psychiatry ,Immunoassay ,Depressive Disorder, Major ,Neuronal Plasticity ,Positive and Negative Syndrome Scale ,biology ,business.industry ,Diagnostic markers ,medicine.disease ,Psychiatry and Mental health ,Schizophrenia ,biology.protein ,Major depressive disorder ,Biological psychiatry ,business - Abstract
To examine the role of neuroplasticity in the pathology of psychiatric disorders, we measured cerebrospinal fluid (CSF) neuroplasticity-associated protein levels. Participants were 94 patients with schizophrenia, 68 with bipolar disorder (BD), 104 with major depressive disorder (MDD), and 118 healthy controls, matched for age, sex, and ethnicity (Japanese). A multiplex immunoassay (22-plex assay) was performed to measure CSF neuroplasticity-associated protein levels. Among 22 proteins, 11 were successfully measured in the assay. CSF amyloid precursor protein (APP) and glial cell-derived neurotrophic factor (GDNF) levels were significantly lower in patients with schizophrenia, and CSF APP and neural cell adhesion molecule (NCAM)-1 levels were significantly lower in patients with BD, than in healthy controls (all p p p p p
- Published
- 2020
45. Possible associations between plasma fibroblast growth factor 21 levels and cognition in bipolar disorder
- Author
-
Kotaro Hattori, Sayuri Ishiwata, Hiroshi Kunugi, Favour Omileke, Shinsuke Hidese, Fuyuko Yoshida, and Junko Matsuo
- Subjects
Adult ,Male ,medicine.medical_specialty ,FGF21 ,Central nervous system ,Neuroprotection ,Cognition ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Effects of sleep deprivation on cognitive performance ,Bipolar disorder ,cognitive impairment ,bipolar disorder ,Pharmacology ,business.industry ,Original Articles ,Middle Aged ,Mental Status and Dementia Tests ,medicine.disease ,Fibroblast Growth Factors ,Psychiatry and Mental health ,Clinical Psychology ,medicine.anatomical_structure ,Mood ,Endocrinology ,Synaptic plasticity ,Original Article ,Female ,business ,Biomarkers - Abstract
Bipolar disorder (BD) is a mental disorder characterized by extreme changes in mood polarity. It is also characterized by cognitive and metabolic dysfunctions. Fibroblast growth factor 21 (FGF21) is an endocrine protein that has a multifaceted function such as glucose and lipid regulation in the periphery, and neuroprotection and induction of synaptic plasticity in the central nervous system. Previous studies reported inconsistent results concerning peripheral FGF21 levels in patients with BD. In this study, we compared plasma FGF21 levels between 26 patients with BD and 51 healthy controls using a human FGF21 ELISA Kit. There was no significant difference in plasma FGF21 levels between the patients and controls. We found significant positive correlations between plasma FGF21 levels and some cognitive parameters (word association and motor speed). If our results are replicated that higher peripheral FGF21 may be associated with better cognitive performance in patients with BD., We compared plasma FGF21 levels between 26 bipolar disorder patients and 51 healthy controls. Although FGF21 concentrations were not different between the patients and controls, we found significant positive correlations between the levels and some cognitive parameters.
- Published
- 2020
46. Neuroanatomical basis of harm avoidance personality traits in major depressive disorder
- Author
-
Kotaro Hattori, Miho Ota, Toshiya Teraishi, Hiroshi Kunugi, Hiroshi Matsuda, Shinsuke Hidese, Ikki Ishida, Yukihito Yomogida, Noriko Sato, and Junko Matsuo
- Subjects
medicine.diagnostic_test ,business.industry ,Depression ,Brain morphometry ,Magnetic resonance imaging ,Neuropathology ,Harm avoidance ,medicine.disease ,behavioral disciplines and activities ,TCI ,mental disorders ,medicine ,Trait ,Major depressive disorder ,Big Five personality traits ,business ,VBM ,vMPFC ,RZ400-408 ,Depression (differential diagnoses) ,Mental healing ,Clinical psychology ,Personality - Abstract
Background : Behavioral inhibition, referred to as the harm avoidance (HA) trait, has been deemed a vulnerability factor for major depressive disorder (MDD). Previous studies tried to find brain structural biomarkers of HA by assessing the relationship between interindividual variability in this trait and brain morphology. However, only healthy participants were recruited for these studies, and the results were heterogeneous. Methods : To clarify the neural link between HA and MDD, we obtained magnetic resonance imaging data from the brains of 331 healthy people and 89 patients with MDD. Voxel-based morphometry (VBM) analyses were conducted to identify brain regions in which the gray matter volume was correlated with the HA score across participants and was simultaneously reduced in MDD patients. Results : We found that the ventral part of the medial preferential cortex (vMPFC) fulfilled these criteria. Limitations : The majority of the patients in this study were medicated with antidepressants. Conclusions : The present finding suggests that reduced gray matter volume in this region is the neuropathology of high HA observed among MDD patients and might be the underlying reason why people with high HA are vulnerable to developing depression. Our findings may contribute to a deeper understanding of the neuropathology of MDD and provide insight into the brain regions of interest for predicting the development of the illness in the future.
- Published
- 2021
47. Association between obesity and white matter microstructure impairments in patients with schizophrenia: A whole-brain magnetic resonance imaging study
- Author
-
Junko Matsuo, Miho Ota, Shinsuke Hidese, Kotaro Hattori, Yuuki Yokota, Hiroshi Kunugi, Ikki Ishida, and Yukihito Yomogida
- Subjects
Adult ,medicine.medical_specialty ,Pittsburgh Sleep Quality Index ,White matter ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,mental disorders ,medicine ,Humans ,Obesity ,Biological Psychiatry ,medicine.diagnostic_test ,Positive and Negative Syndrome Scale ,business.industry ,Brain ,Magnetic resonance imaging ,Voxel-based morphometry ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,White Matter ,030227 psychiatry ,Psychiatry and Mental health ,Diffusion Tensor Imaging ,medicine.anatomical_structure ,Schizophrenia ,Anisotropy ,Female ,business ,Body mass index ,030217 neurology & neurosurgery ,Diffusion MRI - Abstract
We aimed to examine the possible association of obesity (body mass index [BMI] ≥ 30) with symptoms, psychotropic medication, and whole-brain structure in patients with schizophrenia.Participants were 65 patients diagnosed with schizophrenia (mean age: 37.2 ± 11.3 years, 32 females). All participants were Japanese and right-handed. Symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) and Pittsburgh Sleep Quality Index (PSQI). Voxel based morphometry (VBM) and diffusion tensor imaging (DTI) were performed to analyze the association of obesity with gray and white matter structures, respectively.There was no significant difference in PANSS scores between obese and non-obese patients, while the PSQI score was significantly higher in the former than in the latter (p 0.05). The daily dose of typical antipsychotics was significantly higher in obese patients than in non-obese patients (p 0.001). In VBM, there was no significant difference in gray matter volume between obese and non-obese patients. In DTI, fractional anisotropy values in the corpus callosum, corona radiata, corticospinal tract, superior longitudinal fasciculus, and posterior thalamic radiations were significantly lower in obese patients than in non-obese patients (corrected p 0.05). Axial diffusivity was significantly lower while radial and mean diffusivities values were significantly higher in obese patients than in non-obese patients (corrected p 0.05) in similar but more restricted brain regions.Our results suggest that obesity is related to sleep disturbances, daily dose of typical antipsychotics, and regional white matter microstructure impairments in patients with schizophrenia.
- Published
- 2021
48. Altered polyunsaturated fatty acid levels in relation to proinflammatory cytokines, fatty acid desaturase genotype, and diet in bipolar disorder
- Author
-
Hiroshi Kunugi, Norie Koga, Emiko Aizawa, Jun Ogura, Ikki Ishida, Kotaro Hattori, Hiroaki Hori, and Fuyuko Yoshida
- Subjects
0301 basic medicine ,Fatty Acid Desaturases ,Male ,Bipolar Disorder ,chemistry.chemical_compound ,0302 clinical medicine ,Delta-5 Fatty Acid Desaturase ,Surveys and Questionnaires ,Genotype ,chemistry.chemical_classification ,biology ,Interleukin ,Middle Aged ,Eicosapentaenoic acid ,Psychiatry and Mental health ,Fatty Acids, Unsaturated ,Cytokines ,Arachidonic acid ,Female ,lipids (amino acids, peptides, and proteins) ,medicine.symptom ,Polyunsaturated fatty acid ,Adult ,medicine.medical_specialty ,Adolescent ,Inflammation ,Molecular neuroscience ,Polymorphism, Single Nucleotide ,Article ,Proinflammatory cytokine ,lcsh:RC321-571 ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,Young Adult ,Internal medicine ,medicine ,Humans ,lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry ,Biological Psychiatry ,Aged ,business.industry ,Interleukin-6 ,Tumor Necrosis Factor-alpha ,Diet ,030104 developmental biology ,Endocrinology ,Fatty acid desaturase ,chemistry ,biology.protein ,business ,030217 neurology & neurosurgery - Abstract
Inflammation and altered polyunsaturated fatty acid (PUFA) levels have been implicated in bipolar disorder (BD). A recent genome-wide association study identified a locus in the fatty acid desaturase (FADS) gene cluster conferring susceptibility to BD. In this study, we examined PUFA levels in patients with BD in relation to proinflammatory cytokines, FADS genotype, and dietary habits. We enrolled 83 patients with BD and 217 healthy controls who underwent plasma PUFA measurement. A subsample of 65 patients and 90 controls underwent plasma interleukin (IL)-6 and tumor necrosis factor alpha (TNFα) measurement, and three FADS single nucleotide polymorphisms (SNPs) were genotyped. Information on fish consumption was obtained by a self-reported diet history questionnaire. In comparing PUFA levels between patients and controls, significant differences were found for all 7 PUFAs tested. Specifically, n-3 eicosapentaenoic acid (EPA) level was decreased, and n-6 arachidonic acid level was increased in the patients (p FADS genotype, which was associated with increased n-6 PUFA levels, was also associated with marked elevation in TNFα levels. Less frequent fish intake was associated with low EPA and high IL-6 level. Taken together, our results provide strong evidence for altered plasma PUFA and proinflammatory cytokine levels in patients with BD. Furthermore, FADS genotype and fish consumption may contribute not only to altered PUFA levels but also to inflammation in BD.
- Published
- 2019
49. Reduced plasma orexin-A levels in patients with bipolar disorder
- Author
-
Shoko, Tsuchimine, Kotaro, Hattori, Miho, Ota, Shinsuke, Hidese, Toshiya, Teraishi, Daimei, Sasayama, Hiroaki, Hori, Takamasa, Noda, Sumiko, Yoshida, Fuyuko, Yoshida, and Hiroshi, Kunugi
- Subjects
schizophrenia ,bipolar disorder ,Neuropsychiatric Disease and Treatment ,major depressive disorder ,mental disorders ,orexin-A ,plasma ,Original Research - Abstract
Shoko Tsuchimine,1 Kotaro Hattori,1 Miho Ota,1 Shinsuke Hidese,1 Toshiya Teraishi,1 Daimei Sasayama,1 Hiroaki Hori,1 Takamasa Noda,2 Sumiko Yoshida,2 Fuyuko Yoshida,1 Hiroshi Kunugi11Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo 187-8502, Japan; 2Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo 187-8551, JapanPurpose: Orexins are hypothalamic neuropeptides involved in the regulation of sleep, appetite and arousal. An altered orexin system has been implicated in the pathophysiology of psychiatric disorders. This study aimed to examine whether plasma orexin-A levels differ in patients with schizophrenia, major depressive disorder (MDD), or bipolar disorder (BD) compared to in healthy controls. We also examined the possible correlations between plasma orexin-A levels and clinical variables.Patients and methods: All participants were Japanese. The sample consisted of 80 patients with schizophrenia (42 women, 52.5%; mean age 36.8years), 80 patients with MDD (43 women, 53.8%; 43.7years), and 40 patients with BD (24 women, 60%; 41.1years), as well as 80 healthy controls (48 women, 60%; 47.0years). Plasma orexin-A levels were quantified by an enzyme-linked immunosorbent assay.Results: Mean orexin-A levels were significantly different across the four diagnostic groups (F=4.09; df=3; p=0.007, η2=0.06). In particular, the patients with BD showed significantly lower orexin-A levels than did the controls. When the median value of the control group (109.8pg/ml) was set as a cut-off value, subjects whose orexin-A levels were below the cut-off were more common in all psychiatric groups (schizophrenia: 73.8%, x2=9.56, df=1, p=0.003, OR=2.81, 95% CI: 1.45 to 5.45, d=0.57; MDD: 78.5%, x2=14.02, df=1, p
- Published
- 2019
50. Reduced plasma orexin-A levels in patients with bipolar disorder
- Author
-
Toshiya Teraishi, Takamasa Noda, Hiroshi Kunugi, Hiroaki Hori, Shinsuke Hidese, Sumiko Yoshida, Fuyuko Yoshida, Miho Ota, Kotaro Hattori, Shoko Tsuchimine, and Daimei Sasayama
- Subjects
medicine.medical_specialty ,business.industry ,media_common.quotation_subject ,Appetite ,medicine.disease ,Gastroenterology ,Pathophysiology ,030227 psychiatry ,Orexin ,03 medical and health sciences ,Orexin-A ,0302 clinical medicine ,Schizophrenia ,Internal medicine ,mental disorders ,medicine ,Major depressive disorder ,Bipolar disorder ,business ,030217 neurology & neurosurgery ,Depression (differential diagnoses) ,media_common - Abstract
Purpose Orexins are hypothalamic neuropeptides involved in the regulation of sleep, appetite and arousal. An altered orexin system has been implicated in the pathophysiology of psychiatric disorders. This study aimed to examine whether plasma orexin-A levels differ in patients with schizophrenia, major depressive disorder (MDD), or bipolar disorder (BD) compared to in healthy controls. We also examined the possible correlations between plasma orexin-A levels and clinical variables. Patients and methods All participants were Japanese. The sample consisted of 80 patients with schizophrenia (42 women, 52.5%; mean age 36.8 years), 80 patients with MDD (43 women, 53.8%; 43.7 years), and 40 patients with BD (24 women, 60%; 41.1 years), as well as 80 healthy controls (48 women, 60%; 47.0 years). Plasma orexin-A levels were quantified by an enzyme-linked immunosorbent assay. Results Mean orexin-A levels were significantly different across the four diagnostic groups (F=4.09; df=3; p=0.007, η2 =0.06). In particular, the patients with BD showed significantly lower orexin-A levels than did the controls. When the median value of the control group (109.8 pg/ml) was set as a cut-off value, subjects whose orexin-A levels were below the cut-off were more common in all psychiatric groups (schizophrenia: 73.8%, x2 =9.56, df=1, p=0.003, OR=2.81, 95% CI: 1.45 to 5.45, d=0.57; MDD: 78.5%, x2 =14.02, df=1, p
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.